Moreover, individuals with biallelic mutations in SLX4 present with Fanconi anemia (FA), a disease characterized by cancer predisposition and a sensitivity to ICL-inducing agents (Kim et al. 2011; Stoepker et al. 2011). The gene discussed is SLX4; the disease is cancer.